Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Konstantinos Tselios

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
European Journal of Rheumatology|May 21, 2020
Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidenceKonstantinos Tselios, Panagiotis Skendros
Current Rheumatology Reviews|July 6, 2017
Cardiovascular and Pulmonary Manifestations of Systemic Lupus ErythematosusKonstantinos Tselios, Murray B Urowitz
European Journal of Clinical Investigation|October 20, 2017
Discrepancies in reference values of soluble Triggering Receptor Expressed on Myelocytes 1 (sTREM-1) question the reliability of related studiesIoannis Gkougkourelas, Konstantinos Tselios, Panagiota Boura
Frontiers in Neurology|June 14, 2013
The role of anti-phosphatidylserine/prothrombin antibodies in thrombotic manifestations of systemic lupus erythematosus patientsKonstantinos Tselios, Alexandros Sarantopoulos, Ioannis Gkougkourellas, et al.
Clinical & Developmental Immunology|February 5, 2009
Chronic brucellosis patients retain low frequency of CD4+ T-lymphocytes expressing CD25 and CD28 after Escherichia coli LPS stimulation of PHA-cultured PBMCsPanagiotis Skendros, Alexandros Sarantopoulos, Konstantinos Tselios, et al.
Seminars in Arthritis and Rheumatism|November 13, 2018
How can we define low disease activity in systemic lupus erythematosus?Konstantinos Tselios, Dafna D Gladman, Murray B Urowitz
Clinical and Experimental Rheumatology|September 9, 2014
CD4+CD25highFOXP3+ T regulatory cells as a biomarker of disease activity in systemic lupus erythematosus: a prospective studyKonstantinos Tselios, Alexandros Sarantopoulos, Ioannis Gkougkourelas, et al.
Open Access Rheumatology : Research and Reviews|January 6, 2017
Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategiesKonstantinos Tselios, Dafna D Gladman, Murray B Urowitz
Immunotargets and Therapy|December 13, 2023
Managing Cardiovascular Risk in Systemic Lupus Erythematosus: Considerations for the ClinicianTeresa Semalulu, Achieng Tago, Kevin Zhao, et al.
Angiology|July 20, 2004
Antiphospholipid syndrome in Greece: clinical and immunological study and review of the literaturePanagiota Boura, Konstantinos Tselios, Panagiotis Skendros, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
European Journal of Rheumatology|May 21, 2020
Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidenceKonstantinos Tselios, Panagiotis Skendros
Current Rheumatology Reviews|July 6, 2017
Cardiovascular and Pulmonary Manifestations of Systemic Lupus ErythematosusKonstantinos Tselios, Murray B Urowitz
European Journal of Clinical Investigation|October 20, 2017
Discrepancies in reference values of soluble Triggering Receptor Expressed on Myelocytes 1 (sTREM-1) question the reliability of related studiesIoannis Gkougkourelas, Konstantinos Tselios, Panagiota Boura
Frontiers in Neurology|June 14, 2013
The role of anti-phosphatidylserine/prothrombin antibodies in thrombotic manifestations of systemic lupus erythematosus patientsKonstantinos Tselios, Alexandros Sarantopoulos, Ioannis Gkougkourellas, et al.
Clinical & Developmental Immunology|February 5, 2009
Chronic brucellosis patients retain low frequency of CD4+ T-lymphocytes expressing CD25 and CD28 after Escherichia coli LPS stimulation of PHA-cultured PBMCsPanagiotis Skendros, Alexandros Sarantopoulos, Konstantinos Tselios, et al.
Seminars in Arthritis and Rheumatism|November 13, 2018
How can we define low disease activity in systemic lupus erythematosus?Konstantinos Tselios, Dafna D Gladman, Murray B Urowitz
Clinical and Experimental Rheumatology|September 9, 2014
CD4+CD25highFOXP3+ T regulatory cells as a biomarker of disease activity in systemic lupus erythematosus: a prospective studyKonstantinos Tselios, Alexandros Sarantopoulos, Ioannis Gkougkourelas, et al.
Open Access Rheumatology : Research and Reviews|January 6, 2017
Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategiesKonstantinos Tselios, Dafna D Gladman, Murray B Urowitz
Immunotargets and Therapy|December 13, 2023
Managing Cardiovascular Risk in Systemic Lupus Erythematosus: Considerations for the ClinicianTeresa Semalulu, Achieng Tago, Kevin Zhao, et al.
Angiology|July 20, 2004
Antiphospholipid syndrome in Greece: clinical and immunological study and review of the literaturePanagiota Boura, Konstantinos Tselios, Panagiotis Skendros, et al.
Pageof 5